KMT2A and cancer: This indicates that, on the one hand, leukemic transformation can be driven by the GOF KMT2A translocations producing MLL-FPs, while, on the other hand, the development of cancers carrying KMT2A loss-of-function alterations most probably need additional transforming events independent of KMT2A.